Consensus document APAIR: atopic dermatitis in children — update 2019 (short version) Part 2.

Y.S. Smolkin 1,2,11, I.I. Balabolkin 1,3, I.A. Gorlanov 4, L.S. Kruglova 5, A.V. Kudryavtseva 1,6, R.Y. Meshkova 1,7, H.B. Migacheva 1,8, R.F. Khakimova 1,9, A.A. Cheburkin 1,10, E.A. Kuropatnikova 1,11, N.A. Lyan 1,6, A.V. Maksimova 1,11, S.S. Masalskiy 1,11, O.Y. Smolkina 1,11

1 Association Pediatric Allergist and Immunologist Russia, Moscow;
2 Academy postgraduate education «Federal State Budget Founding Federal Research and Clinical Center of specialized types of health care and medical technology of the Federal Medical and Biological Agency», Moscow;
3 National Medical Research Center for Children’s Health Federal state autonomous institution of the Russian Federation Ministry of Health, Moscow;
4 St. Petersburg State Pediatric Medical University, St. Petersburg;
5 Central State Medical Academy of Department of President Affairs, Moscow;
6 Sechenov First Moscow State Medical University, Moscow;
7 Federal State Budgetary Educational Institution of Higher Education «Smolensk State Medical University» of Ministry of Healthcare of the Russian Federation, Smolensk;
8 Federal State Budgetary Educational Institution of Higher Education «V.I. Razumovsky Saratov State Medical University» of Ministry of Healthcare of the Russian Federation, Saratov;
9 Federal State Budgetary Educational Institution of Higher Education «Kazan State Medical University» of Ministry of Healthcare of the Russian Federation, Kasan;
10 Russian Medical Academy of Postgraduate Education, Moscow;
11 «Scientific-Clinical Consultative Center of Allergology and Immunology», L.t.d, Moscow.

ALLERGOLOGY AND IMMUNOLOGY IN PEDIATRICS, Volume 61 • Number 2 • June 2020, pp. 4 – 26
DOI: 10.24411/2500-1175-2020-10004

Atopic dermatitis (AD) is a diagnosis with precise criteria described by Hanifin & Rajka. A differential diagnosis should be considered at the discrepancy of the symptoms or torpid eczema. The list of diseases is genetic syndromes with the impaired epidermal barrier, metabolic diseases, skin infections, psoriasis and others. Skin infections in the diagnostic search should be considered the first time.
The basis of therapy allergic eczema is the elimination of allergenic and non-allergenic triggers, topical steroids and inhibitors calcineurin with uses of emollients in the skincare process. This therapy is sufficient for most patients.
Systemic therapy of dermatitis consists of short courses of steroids (up to 1 week) with the ineffectiveness of external preparation. If long-term therapy is necessary, it is proposed to consider the possibility of prescribing dupilumab and cyclosporin A.
Antihistamines can be considered as a drug for stopping itching in the early days of the disease. With a sufficient effect of external anti-inflammatory drugs, the use of antihistamines is not required.
Exclusion of culpable food allergens leads to rapid remission of the disease. Non-specific hypoallergenic diets reduce the quality of life of patients and should not be used for a long time. The main formula for feeding children with allergies to cow’s milk protein is extensively hydrolysed formula. The amino acid-based formula is reserved for severe cases.
During the period of remission, it is important to provide skincare and regular use of emollients, as well as a complex to eliminate causative allergens from the patient’s environment.
Specific immunotherapy can be recommended for patients with a proven role of the allergen in the development of exacerbation AD and with a combination of eczema with allergic rhinoconjunctivitis and asthma.

  1. Lyons J.J., Milner J.D., Stone K.D. Atopic Dermatitis in Children: Clinical Features, Pathophysiology, and Treatment. Immunol. Allergy Clin. North Am. 2015; 35(1): 161–183.
  2. Zhang L.Y., Tian W., Shu L. et al. Clinical Features, STAT3 Gene Mutations and Th17 Cell Analysis in Nine Children with Hyper-IgE Syndrome in Mainland China. Scand. Immunol. 2013; 78(3): 258–65.
  3. Tom W.L. Eichenfield Eczematous disorders. In: Eichenfield L.F., Frieden I.J., Mathes E.F., Zaenglein A.L. Neonatal and Infant Dermatology. Third edition. ELSEVIER 2015: 216–232.
  4. Kawasaki Y., Toyoda , Otsuki S. et al. Anovel Wiskott-Aldrich syndrome protein mutation in an infant with thrombotic thrombocytopenic purpura. Eur.J. Haematol. 2013; 90(2): 164–168.
  5. Tavil , Erdem A.Y., Azik F. et al. Successful allogeneic hemopoietic stemcell transplantation in a case of Wiskott-Aldrich syndrome and non-Hodgkin lymphoma. Pediatr. Transplant. 2013; 17(6):E146–E148.
  6. Jesenak M., Plamenova I., Plank , Banovcin P. Wiskott-Aldrich syndrome caused by a new mutation associated with multifocal dermal juvenile xanthogranulomas. Pediatr. Dermatol. 2013; 30(5):91–94.
  7. Thyssen J.P., Godoy-Gijon , Elias P.M. Ichthyosis vulgaris: the filaggrin mutation disease. Br J Dermatol.2013; 168: 1155–1166.
  8. Fortugno P., Bresciani A., Paolini C. Proteolytic activation cascade of the Netherton syndrome — defective protein, LEKTI, in the epidermis: implications for skin homeostasis J Invest 2011; 131: 2223–2232.
  9. Gelmetti C.M., Grimalt R. Infantile Seborrhoeic Dermatitis In: Irvin A.D., Hoeger H.P., Yan A.C. Harper’s Textbook of Pediatric Dermatology, third edition, 2011; 35: 1–35.8.
  10. Gelmetti C., Frasin A.L. Infantile seborrhoeic dermatitis: a disappearing disease. Eur J Pediatr Dermatol. 2008; 18: 155–156.
  11. Karadag A.S., Bilgili S.G., Calka O. Acrodermatitis enteropathica in three siblings Indian J Dermatol, Venereol Leprol. 2013; 79 (2): 268–269.
  12. Ashkenazi-Hoffnung L., Bilavsky E., Amir J. Acrodermatítis enteropathica in a 9-month-old infant. Israel Medical Association J. 2011; 13(4): 258.
  13. Jung A.G., Mathony U.A., Behre B., Küry S., Schmitt S. et al. Acrodermatitis enteropathica: an uncommon differential diagnosis in childhood — first description of a new sequence variant. J Deutsch Dermatol Gesellschaft. 2011; 9(12): 999–1002.
  14. Minkov M. Multisystem Langerhans Cell Histiocytosis in Children. Paediatr Drugs. 2011; 13(2): 75–86.
  15. Larralde M. Langerhans cell histiocytosis in children under one year. Arch Argent Pediatr. 2008; 106(3): 269–272.
  16. Shmidt E., Levitt J. Dermatologic infestations International Journal of Dermatology. 2012; 51: 131–141.
  17. Nowicka D., Grywalska E. The Role of Immune Defects and Colonization of Staphylococcus aureus in the Pathogenesis of Atopic Dermatitis. Analytical CellularPathology. 2018; 5: 7 p.
  18. Wollenberg A., Barbarot T., Bieber T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018; 32: 657–682.
  19. Eichenfield L.F., Tom W.L., Berger T.G. et al. Guidelines of care for the management of atopic dermatitis, section 2: management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014; 71(1): 116–132.
  20. Åkerström U., Reitamo S., Langeland T. et al. Comparison of moisturizing creams for the prevention of atopic dermatitis relapse: A randomized double-blind controlled multicentre clinical trial. Acta Derm. Venereol. 2015; 95(5): 587–592.
  21. Pelc J., Czarnecka-Operacz M., Adamski Z. The structure and function of the epidermal barrier in patients with atopic dermatitis – Treatment options. Part two. Postep. Dermatologii i Alergol. 2018; 35(2): 123–127.
  22. Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis / Ou Z., Chen C., Chen A., [et al.] International immunopharmacology. — 2018. — Т. 54. — С. 303–310.
  23. Werfel T., Wollenberg A., Pumnea T., Heratizadeh A. Neues in der Systemtherapie der atopischen Dermatitis. Hautarzt . 2018; 69(3): 217–224.
  24. Berth-Jones J., Graham-Brown R.A.C. Treatment of itching in atopic eczema. Br Med J. 1989; 298: 491–492.
  25. Kemp J.P. Tolerance induction to antihistamines: Is it a problem? AnnAllergy. 1995; 50: 7–11.
  26. Российский национальный согласительный документ по атопическому дерматиту. Атопический дерматит: применение антигистаминных препаратов. — М.: «Фармарус Принт», 2002. — 24 с.
  27. Ferrer M., Morais-Almeida M., Guizova M., Khanferyan R. Evaluation of treatment satisfaction in children with allergic disease treated with an antihistamine: an international, non-interventional, retrospective study. Clin Drug Investig. 2010; 30(1): 15–34.
  28. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус Принт», 1998.
  29. Diepgen T.L. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol. Aug-2002; 13(4): 278–286.
  30. Nassif A., Chan S.C., Storrs F.J. et al. Abnormal skin irritancy in atopic dermatitis and in atopy without dermatitis. Arch Dermatol 1994; 130: 1402–1407.
  31. Bremmer S.F., Simpson E.L. Dust mite avoidance for the primary prevention of atopic dermatitis: A systematic review and meta-analysis. Pediatric Allergy andImmunology. Nov 2015; 26(7), 646–654.
  32. Nankervis H., Pynn E.V. et al. House dust mite reduction and avoidance measures for treating eczema (Review). The Cochrane Collaboration. 2015.
  33. Sanda T., Yasue T., Oohashi M. et al. Effectiveness of house dust-mite allergen avoidance through clean room therapy in patients with atopic dermatitis. J Allergy Clin Immunol 1992; 89: 653–657.
  34. Bock S.A., Atkins F.M. Patterns of food hypersensitivity during sixteen years of double-blind, placebo-controlled food challenges. J Pediatr 1990; 117: 561–567.
  35. Young M.C. Elimination Diets in Eczema—A Cautionary Tale. The Journal of Allergy and Clinical Immunology: In Practice. 2016, V.4, Issue 2, P. 237–238.
  36. Chang A., Robison R., Cai M., Singh A.M. Natural history of food triggered atopic dermatitis and development of immediate reactions in children. J Allergy Clin Immunol Pract. 2016 Mar-Apr; 4(2): 229–236.
  37. Kim J.S., Nowak-Wegrzyn A., Sicherer S.H., Noone S., Moshier E.L., Sampson H.A. Dietary baked milk accelerates the resolution of cow’s milk allergy in children. The Journal of Allergy and Clinical Immunology. 2011; 128(1): 125–131.
  38. Sampson H.A. The immunopathogenic role of food hypersensitivity in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1992; 176: 34–37.
  39. Bergmann M.M., Caubet J.C., Boguniewicz M., Eigenmann P.A. Evaluation of food allergy in patients with atopic dermatitis. The Journal of Allergy and Clinical Immunology: In Practice. 2013; 1(1): 22–28.
  40. Zeiger R.S. Use of elemental formulas: Hydrolysates in allergy prevention. Ross Conference 107th: Physiologic/Immunologic Responses to Dietary Nutrients: Role of Elemental and Hydrolysate Formulas in Management of the Pediatric Patient. Ross Products Publishers, Columbus, Ohio, 1998: 108–126.
  41. Fiocchi A. et al. World Allergy Organization (WAO) diagnosis and rationale for action against CMA (DRACMA) guidelines. Pediatr Allergy immunol 2010; 21(suppl 21): 1–125.
  42. Meyer R.et al. Malnutrition in children with food allergies in the UK. J Hum Nutr Diet. 2013; 27, 227–235.
  43. Koletzko S. et al. Diagnostic approach and management of CMA in infants and children: ESPGHAN GI Committee practical guidelines. J Pediatr Gastroenterol Nutr, 2012: 221–229.
  44. Ludman S. et al. Managing CMA in children. BMJ. 2013; 347: 355.- 186.
  45. Venter C. et al. Diagnosis and management of non-IgE-mediated CMA in infancy — a UK primary care practical guide. Clin Transl Allergy. 2013; 3(1): 23.
  46. Hill D.J. et al. The efficacy of amino AAF in relieving the symptoms of CMA: a systematic review. Clin Exp Allergy. 2007 Jun; 37(6): 808–822.
  47. Luyt D et al. Standards of Care Committee (SOCC) of the BSACI. BSACI guideline for the diagnosis and management of CMA. Clin. Exp. Allergy 2014, 44, 642–672.
  48. Meyer R. et al. When Should Infants with Cow’s Milk Protein Allergy Use an Amino Acid Formula? A Practical Guide. J Allergy Clin Immunol Pract 2017 Mar-Apr; 6(2): 383–399.
  49. Antunes J. et al. Allergy to eHF. Allergol Immunopathol. 2009; 37: 272–274.
  50. Liacouras C.A. et al. EoE: a 10-year experience in 381 children. ClinGastroenterol Hepatol. 2001; 3(12): 1198–1206.
  51. Gil K.M., Sampson H.A. Psychological and social factors of atopic dermatitis. Allergy 9S: 84–89.
  52. White A., Horne D.J., Varigos G.A. Psychological profile of the atopic eczema patient. Australas J Dermatol 1990; 31: 13–16.
  53. Noren P., Melin L. The effect of combined topical steroids and habit-reversal treatment in patients with atopic dermatitis. Br J Dermatol 1989; 121: 359–366.
  54. Melin L., Frederiksen T., Noren P. et al. Behavioral treatment of scratching in patients with atopic dermatitis. Br J Dermatol 1986; 115: 467–474.
  55. Horne D.J., White A.E., Varigos G.A. A preliminary study of psychological therapy in the management of atopic eczema. Br J Med Psychol 1989; 62: 241–248.
  56. Haynes S.N., Wilson C.C., Jaffe P.G. et al. Biofeedback treatment of atopic dermatitis: controlled case studies of eight cases. Biofeedback Self Regul 1979; 4: 195–209.
  57. Wollenberg A., Barbarot T., Bieber T. et al Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850–878.
  58. Sidbury R., Davis D.M., Cohen D.E. et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J. Am. Acad. Dermatol. 2014; 71(2): 327–349.
  59. Астафьева Н.Г., Кобзев Д.Ю. Между верой и знанием: официальная, альтернативная и комплементарная медицина в лечении астмы и аллергии (часть 1). Лечащий врач. 2012, № 6: 59–62.
  60. Астафьева Н.Г., Кобзев Д.Ю. Между верой и знанием: официальная, альтернативная и комплементарная медицина в лечении астмы и аллергии (часть 2). Лечащий врач. 2012, № 8: 74–77.
  61. «Атопический дерматит у детей: обновление 2019 (на правах руководства)». Согласительный документ Ассоциации детских аллергологов и иммунологов России. Москва: АДАИР, 2019; Cамара: ООО «Полиграфическое объединение «Стандарт», 2019. — 222 с.
  62. Приказ Министерства здравоохранения РФ от 7 июня 2018 г. № 321н «Об утверждении перечней медицинских показаний и противопоказаний для санаторно-курортного лечения» ГАРАНТ.РУ: http://www.garant.ru/products/ipo/ prime/doc/71879402/#ixzz5Qak8NB83
  63. Погонченкова И.В., Рассулова М.А., Хан М.А., Лян Н.А. и др. Современные технологии медицинской реабилитации детей с атопическим дерматитом//Доктор.Ру. 2016. №12 (129). Часть 2. С. 44–47.
  64. Смолкин Ю.С., Балаболкин И.И., Горланов И.А. и др. Атопический дерматит у детей: обновление 2019 (на правах руководства). Согласительный документ Ассоциации детских аллергологов и иммунологов России. Краткая версия. Часть 1. Аллергология и иммунология в педиатрии 2020; 60 (1): 4–25, https://doi.org/10.24411/2500-1175-2020-10001
  65. Glover M.T., Atherton D.J. A doubleblind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Ex Allergy. 1992; 22: 440–446.
  66. Максимова А.В., Смолкин Ю.С. Аллергические реакции к компонентам вакцин в обосновании тактики профилактической вакцинации чувствительных пациентов: аналитический обзор. Педиатрия. Приложение к журналу Consilium Medicum 2019; 3: 24–32.

Smolkin YS, Balabolkin II, Gorlanov IA, Kruglova LS, Kudryavtseva AV, Meshkova RY, Migacheva HB, Khakimova RF, Cheburkin AA, Kuropatnikova EA, Lyan NA, Maksimova AV, Masalskiy SS, Smolkina OY. Consensus document APAIR: atopic dermatitis in children — update 2019 (short version) part 2. Allergology and Immunology in Pediatrics. 2020;61(2):4-26. (In Russ.) https://doi.org/10.24411/2500-1175-2020-10004

For correspondense

Yury S. Smolkin, doctor of medical sciences, professor of Department of Clinical Immunology and Allergology Academy of postgraduate educational under FSBU FSCC of FMBA, vicepresident APAIR
ORCID ID: 0000-0001-7876-6258
Address: 6 Ostrovityanova Str., Moscow, 117513, Russia
E-mail: smolking@df.ru

ALLERGOLOGY and IMMUNOLOGY in PEDIATRICS

Spelling error report

The following text will be sent to our editors: